AC Immune SA
ACIUAC Immune SA is a Swiss biopharmaceutical company focused on developing therapies for neurodegenerative and age-related diseases, including Alzheimer's and Parkinson's. It specializes in innovative platforms such as antibody and vaccine development to target misfolded proteins associated with these conditions.
Company News
AC Immune reported promising interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein, showing potential to slow Parkinson's disease progression with a strong safety profile and 100% antibody responder rate.
AC Immune reported Q3 2025 financial results, highlighting a strategic refocus on high-value neurodegenerative disease assets, reducing workforce by 30%, and maintaining cash resources until Q3 2027. The company is progressing multiple clinical-stage immunotherapy and small molecule programs targeting neurodegenerative diseases.
AC Immune is reducing workforce by 30% to focus on late-stage clinical development of neurodegenerative disease therapies, extending cash runway to Q3 2027 and maintaining key clinical milestones.
AC Immune reported Q2 2025 financial results, highlighting progress in neurodegenerative disease therapies with three active immunotherapies in Phase 2 clinical development and a cash balance of CHF 127.1 million providing funding into Q1 2027.
AC Immune reported positive interim results from its Phase 2 trial of ACI-7104.056, an anti-alpha-synuclein active immunotherapy for Parkinson's disease. The company also highlighted progress in its early-stage pipeline and provided financial updates.
